Stock SYG SYGNIS SA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sygnis SA

Equities

SYG

PLMODE000019

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 23:00:00 26/05/2024 BST 		5-day change 1st Jan Change
0.586 PLN -6.09% Intraday chart for Sygnis SA -4.25% -34.60%
02-14 Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
02-14 Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 2.661 1.833 2.566 17.15 12.36 52.54
Enterprise Value (EV) 1 2.189 1.527 2.522 16.59 8.591 55.24
P/E ratio -34.9 x -9.71 x -8.39 x 56.4 x 118 x -23.4 x
Yield - - - - - -
Capitalization / Revenue 1.01 x 0.73 x 1.12 x 6.14 x 3.64 x 1.84 x
EV / Revenue 0.83 x 0.61 x 1.1 x 5.94 x 2.53 x 1.94 x
EV / EBITDA -67.7 x -23.5 x -9.12 x 20 x 13.6 x -55.8 x
EV / FCF 4.47 x 43.3 x -49.7 x -41.2 x -2.44 x 5.43 x
FCF Yield 22.4% 2.31% -2.01% -2.43% -41% 18.4%
Price to Book 2.05 x 1.65 x 3.19 x 15.5 x 1.34 x 1.46 x
Nbr of stocks (in thousands) 5,913 5,913 5,913 5,913 5,913 22,743
Reference price 2 0.4500 0.3100 0.4340 2.900 2.090 2.310
Announcement Date 25/05/18 24/05/19 16/03/20 19/03/21 21/03/22 20/03/23
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 2.633 2.521 2.285 2.795 3.395 28.51
EBITDA 1 -0.0323 -0.0649 -0.2765 0.8304 0.6318 -0.9908
EBIT 1 -0.0563 -0.1894 -0.2825 0.3399 0.4863 -1.233
Operating Margin -2.14% -7.51% -12.36% 12.16% 14.32% -4.32%
Earnings before Tax (EBT) 1 -0.0763 -0.1887 -0.306 0.3038 0.4387 -2.031
Net income 1 -0.0763 -0.1887 -0.306 0.3038 0.4036 -2.244
Net margin -2.9% -7.49% -13.39% 10.87% 11.89% -7.87%
EPS 2 -0.0129 -0.0319 -0.0517 0.0514 0.0177 -0.0987
Free Cash Flow 1 0.4898 0.0352 -0.0507 -0.403 -3.524 10.17
FCF margin 18.61% 1.4% -2.22% -14.42% -103.81% 35.67%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 25/05/18 24/05/19 16/03/20 19/03/21 21/03/22 20/03/23
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - 2.7
Net Cash position 1 0.47 0.31 0.04 0.56 3.77 -
Leverage (Debt/EBITDA) - - - - - -2.73 x
Free Cash Flow 1 0.49 0.04 -0.05 -0.4 -3.52 10.2
ROE (net income / shareholders' equity) -5.7% -15.7% -32% 31.8% 2.2% -10.4%
ROA (Net income/ Total Assets) -1.65% -6.38% -11.6% 10.5% 1.11% -1.37%
Assets 1 4.614 2.96 2.638 2.904 36.5 163.6
Book Value Per Share 2 0.2200 0.1900 0.1400 0.1900 1.560 1.580
Cash Flow per Share 2 0.0800 0.0500 0.0300 0.1400 0.1900 0.0300
Capex 1 0.11 0.08 0.19 0.37 1.87 1.29
Capex / Sales 4.05% 3.27% 8.15% 13.33% 55.14% 4.53%
Announcement Date 25/05/18 24/05/19 16/03/20 19/03/21 21/03/22 20/03/23
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SYGNIS SA Stock Sygnis SA
-34.60% 3.77M
MODERNA, INC. Stock Moderna, Inc.
+52.34% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.33% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.38% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.55% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.86% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.06% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.83% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SYG Stock
  4. Financials Sygnis SA